Correction to: npj Precision Oncology 10.1038/s41698-024-00552-7, published online 16 April 2024
In the Acknowledgements section, the funding source was omitted. The original article has been corrected.
. 2024 Jul 15;8:142. doi: 10.1038/s41698-024-00633-7
Author Correction: BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape
David Planchard
1,✉, Rachel E Sanborn
2, Marcelo V Negrao
3, Aria Vaishnavi
4, Egbert F Smit
5
David Planchard
1Thoracic Cancer Group, Department of Medical Oncology, Gustave Roussy, Villejuif, France
Find articles by David Planchard
Rachel E Sanborn
2Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR USA
Find articles by Rachel E Sanborn
Marcelo V Negrao
3Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX USA
Find articles by Marcelo V Negrao
Aria Vaishnavi
4Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX USA
Find articles by Aria Vaishnavi
Egbert F Smit
5Department of Pulmonary Disease, Leiden University Medical Centre, Leiden, Netherlands
Find articles by Egbert F Smit
1Thoracic Cancer Group, Department of Medical Oncology, Gustave Roussy, Villejuif, France
2Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR USA
3Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX USA
4Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX USA
5Department of Pulmonary Disease, Leiden University Medical Centre, Leiden, Netherlands
✉
Corresponding author.
Collection date 2024.
Subject terms: Non-small-cell lung cancer, Targeted therapies
© The Author(s) 2024
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
PMCID: PMC11250813 PMID: 39009670
This corrects the article "BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape", 90.